T
TrialNavigatorAI

Confidential Preview

This is a private prototype. Please enter the access password to continue.

Prototype demo. All metrics, regional data, and trial pipeline figures below are synthetic. No individual patient data is shown in sponsor views — only de-identified aggregates. TrialNavigatorAI does not exchange identifiable patient information with sponsors.
Customized preview prepared for Rakuten Medical. All metrics shown are synthetic projections illustrating what a sponsored pilot could look like. This view does not represent an existing partnership or actual Rakuten Medical program data.
Partner View

Sponsor dashboard

—

Population reach

The HNSCC patient population TrialNavigatorAI supports across community oncology partners. Click any panel for methodology and breakdowns.

Biomarker awareness

Patients with documented testing
Details
HPV tested
81%
PD-L1 (CPS)
62%
EGFR / EBV
48%
Full NGS
31%

Trial readiness distribution

Across active HNSCC panel
Details
Trial-ready
8 (50%)
In progress
5 (31%)
Early stage
2 (12%)
Flagged
1 (7%)

Regional reach

Community oncology partners
Details
Northeast
4
2 clinics · 4 navigators
South
5
3 clinics · 5 navigators
Midwest
3
2 clinics · 2 navigators
West
4
2 clinics · 3 navigators

Demographic diversity

Aggregate, de-identified
Details

Race / ethnicity

White56%
Hispanic/Latino19%
Black14%
Asian / Pacific Is.8%
Other / declined3%

Setting

Community87%
Academic-affiliated13%

Language

English76%
Spanish18%
Other6%

Sponsored trial pipeline

—

Cost per qualified referral
$2,840
Synthetic projection · Q2 2026
Industry benchmark (site-based)$6,000–9,000
TrialNavigatorAI (community network)$2,840
Estimated savings vs. baseline~60%
Sponsor pays only for qualified referrals — defined as a patient + records package reviewed and accepted by the trial site. No payment for unqualified leads. Patient-facing experience remains non-promotional.

Quality indicators

Across qualified referrals delivered
Records complete
94%
Biomarker present
88%
Site screen-accept
71%
Enrolled (of screened)
56%
Industry-typical site screen-accept rate is roughly 30–40%. Higher rates reflect upstream readiness work done at the community level.

Governance & data principles

How sponsor data flows are structured — and what sponsors never see.

No PHI to sponsors
Sponsors never receive identifiable patient information. All sponsor dashboards show de-identified aggregates only.
Patient-led referral
Patients are referred to trials only after their oncology team approves and they consent. Sponsors do not initiate outreach.
Non-promotional experience
Patient-facing content is curated by clinical and editorial review, not by sponsors. Sponsor logos do not appear in patient views.
Audit-ready
All AI outputs and clinician approvals are logged with timestamps. Sponsors receive aggregate quality reports, not patient-level access.